Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Topics Community

Article

Polymorphisms in candidate genes: implications for the current treatment of Parkinson's disease.

Expert opinion on pharmacotherapy - 1 May 2006

Skipper Lisa, Liu Jian-Jun, Tan Eng-King

Abstract excerpt

Pharmacological treatment remains the cornerstone of therapy in Parkinson's disease. A number of clinical and genetic factors may influence the therapeutic response and treatment-related complications. Some exploratory studies have suggested that genetic polymorphisms may influence an individual's response to dopaminergic therapy and susceptibility to drug-related complications, such as hallucinations,...

Topics

Animals
Antiparkinson Agents
Genetic Variation
Humans
Parkinson Disease
Polymorphism, Genetic

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 16634708
DOI: 10.1517/14656566.7.7.849

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Polymorphisms in candidate genes: implications for the current treatment of Parkinson's disease.PMID 16634708Read ↗

Advances in understanding genomic markers and pharmacogenetics of Parkinson's disease.Semantic proximity Read ↗

Pharmacogenetics of antiparkinsonian drug treatment: a systematic review.Semantic proximity Read ↗

Genetics and Treatment Response in Parkinson’s Disease: An Update on Pharmacogenetic StudiesSemantic proximity Read ↗

Pharmacogenomics—a New Frontier for Individualized Treatment of Parkinson’s DiseaseSemantic proximity Read ↗

Dopaminergic Pathway Genes Influence Adverse Events Related to Dopaminergic Treatment in Parkinson's DiseaseSemantic proximity Read ↗

Genetic substrates of psychosis in patients with Parkinson's disease: A critical reviewSemantic proximity Read ↗

Parkinson’s Disease Pharmacogenomics: New Findings and PerspectivesSemantic proximity Read ↗

Anti-Parkinson's disease drugs and pharmacogenetic considerationsSemantic proximity Read ↗

Pharmacogenetics and levodopa induced motor complicationsSemantic proximity Read ↗

Genetic factors involved in the pathogenesis of Parkinson's diseaseSemantic proximity Read ↗

Clinical and Clinical-Pharmacogenetic Models for Prediction of the Most Common Psychiatric Complications Due to Dopaminergic Treatment in Parkinson's Disease.Semantic proximity Read ↗

The Role of Single Nucleotide Polymorphisms of Monoamine Oxidase B, Dopamine D2 Receptor, and DOPA Decarboxylase Receptors Among Patients Treated for Parkinson's Disease.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.